Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | CFO and Treasurer | July 16, 2026 | July 18, 2026 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | CHIEF FINANCIAL OFFICER | August 24, 2023 | February 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date July 16, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 143,149 |
Reported balance
After 2026-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 85,130 · Balance 143,149 F1: These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2: Includes, as of the transaction date, (i) 85,130 unvested RSUs granted on July 16, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (ii) 58,019 unvested RSUs granted on December 8, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.81 · Expires 2036-07-16 | Direct | 136,363 |
Reported balance
After 2026-07-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-16 · Grant · Acquired 136,363 · Balance 136,363 F3: This option was granted to the Reporting Person on July 16, 2026, and will vest over four years, with 25% of the shares subject to the option vesting on the one-year anniversary of the date of grant, and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, becoming fully vested on July 16, 2030 in accordance with the Plan, subject to the Reporting Person's continued service as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2: Includes, as of the transaction date, (i) 85,130 unvested RSUs granted on July 16, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (ii) 58,019 unvested RSUs granted on December 8, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F3: This option was granted to the Reporting Person on July 16, 2026, and will vest over four years, with 25% of the shares subject to the option vesting on the one-year anniversary of the date of grant, and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, becoming fully vested on July 16, 2030 in accordance with the Plan, subject to the Reporting Person's continued service as of the applicable vesting date.
Verrica Pharmaceuticals Inc.
Report date August 24, 2023 · Filed February 06, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,000 |
Reported balance
After 2023-08-24 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2023-08-24 · Grant · Acquired 125,000 · Balance 125,000 F1: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale. F2: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale.
F2: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OptiNose, Inc.
Report date May 21, 2025 · Filed May 21, 2025
Section 16 reporting ended · disclosed 2025-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 30,541 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, (i) each outstanding and vested restricted stock unit ("RSU") was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR and (ii) each outstanding and unvested RSU was canceled, with the holder thereof contingently entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR, with such consideration vesting and becoming payable, if at all, at the same time as the unvested RSU would have vested and been payable pursuant to its terms. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.65 · Expires 2034-10-07 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 45,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.77 · Expires 2035-02-21 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 6,950 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.
F3: Pursuant to the Merger Agreement, at the Effective Time, (i) each outstanding and vested restricted stock unit ("RSU") was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR and (ii) each outstanding and unvested RSU was canceled, with the holder thereof contingently entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR, with such consideration vesting and becoming payable, if at all, at the same time as the unvested RSU would have vested and been payable pursuant to its terms.
F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 18, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (Right to Buy) · Derivative | 136,363 | $0.00 Strike: $8.81 | $0.00 |
DisclosureSEC source: 0001140361-26-028844 · form4.xml · derivative · entry 2 Kohler Terry · CIK 0001872285 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,363 Underlying: Common Stock · 136,363 shares Expires 2036-07-16 F3 · derivative.exercise_date: This option was granted to the Reporting Person on July 16, 2026, and will vest over four years, with 25% of the shares subject to the option vesting on the one-year anniversary of the date of grant, and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, becoming fully vested on July 16, 2030 in accordance with the Plan, subject to the Reporting Person's continued service as of the applicable vesting date. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 85,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-028844 · form4.xml · nonDerivative · entry 1 Kohler Terry · CIK 0001872285 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,149 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: Includes, as of the transaction date, (i) 85,130 unvested RSUs granted on July 16, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (ii) 58,019 unvested RSUs granted on December 8, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| May 21, 2025 Filed May 21, 2025 13:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,950 | Not disclosed Strike: $5.77 | Not disclosed |
DisclosureSEC source: 0001104659-25-051349 · tm2515648-10_4seq1.xml · derivative · entry 3 Kohler Terry · CIK 0001872285 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,950 shares Expires 2035-02-21 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 21, 2025 Filed May 21, 2025 13:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 45,000 | Not disclosed Strike: $10.65 | Not disclosed |
DisclosureSEC source: 0001104659-25-051349 · tm2515648-10_4seq1.xml · derivative · entry 2 Kohler Terry · CIK 0001872285 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2034-10-07 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 21, 2025 Filed May 21, 2025 13:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerCommon Stock | 30,541 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-051349 · tm2515648-10_4seq1.xml · nonDerivative · entry 1 Kohler Terry · CIK 0001872285 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2 · price: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, (i) each outstanding and vested restricted stock unit ("RSU") was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR and (ii) each outstanding and unvested RSU was canceled, with the holder thereof contingently entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR, with such consideration vesting and becoming payable, if at all, at the same time as the unvested RSU would have vested and been payable pursuant to its terms. Read SEC document |
| February 21, 2025 Filed Feb 27, 2025 01:00 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 6,950 | $0.00 Strike: $5.77 | $0.00 |
DisclosureSEC source: 0001494650-25-000011 · wk-form4_1740618037.xml · derivative · entry 2 Kohler Terry · CIK 0001872285 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,950 Underlying: Common Stock · 6,950 shares Expires 2035-02-21 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 21, 2025. Twenty-five percent (25%) of the option vests and becomes exercisable on February 21, 2026, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| February 21, 2025 Filed Feb 27, 2025 01:00 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 13,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-25-000011 · wk-form4_1740618037.xml · nonDerivative · entry 1 Kohler Terry · CIK 0001872285 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,875 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on February 21, 2026, and the balance vests in equal quarterly installments over the remaining three years of the four year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| October 07, 2024 Filed Oct 7, 2024 22:40 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 675,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001494650-24-000145 · wk-form4_1728340805.xml · derivative · entry 2 Kohler Terry · CIK 0001872285 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2034-10-07 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on October 7, 2024. Twenty-five percent (25%) of the option vests and becomes exercisable on October 7, 2025, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| October 07, 2024 Filed Oct 7, 2024 22:40 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-24-000145 · wk-form4_1728340805.xml · nonDerivative · entry 1 Kohler Terry · CIK 0001872285 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on October 7. 2025, and the balance vests in equal quarterly installments over the remaining three years of the four year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 7,899 | $2.46 | $19,431.54 |
DisclosureSEC source: 0001415889-24-022424 · form4-08282024_040804.xml · nonDerivative · entry 2 Kohler Terry · CIK 0001872285 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,697 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.53 inclusive. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 21,820 | $2.66 | $58,041.20 |
DisclosureSEC source: 0001415889-24-022424 · form4-08282024_040804.xml · nonDerivative · entry 1 Kohler Terry · CIK 0001872285 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,596 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:31 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001415889-24-008541 · form4-03192024_040349.xml · derivative · entry 2 Kohler Terry · CIK 0001872285 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2034-03-15 F2 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 15, 2025 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:31 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008541 · form4-03192024_040349.xml · nonDerivative · entry 1 Kohler Terry · CIK 0001872285 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,416 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028 subject to the Reporting Person's continuous service through each applicable date. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:34 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 9,632 | $2.97 | $28,607.04 |
DisclosureSEC source: 0001209191-23-055531 · doc4.xml · nonDerivative · entry 2 Kohler Terry · CIK 0001872285 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,416 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $3.00 inclusive. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:34 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 18,452 | $2.93 | $54,064.36 |
DisclosureSEC source: 0001209191-23-055531 · doc4.xml · nonDerivative · entry 1 Kohler Terry · CIK 0001872285 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,048 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 20:40 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-047524 · doc4.xml · nonDerivative · entry 1 Kohler Terry · CIK 0001872285 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 F1 · shares: Represents vesting of shares of common stock underlying performance stock units resulting from the achievement of certain non-financial milestones. These shares have not been delivered. Read SEC document |
| August 24, 2023 Filed Feb 6, 2025 21:15 UTC Amendment | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003233 · form4a-02062025_040208.xml · nonDerivative · entry 1 Kohler Terry · CIK 0001872285 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale. F2 · shares: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction. F2 · balance_after: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:27 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $7.58 | $0.00 |
DisclosureSEC source: 0001209191-23-015503 · doc4.xml · derivative · entry 1 Kohler Terry · CIK 0001872285 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 21:33 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013196 · doc4.xml · derivative · entry 1 Kohler Terry · CIK 0001872285 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-23 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on February 24, 2023 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 22:04 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $10.28 | $0.00 |
DisclosureSEC source: 0001209191-21-047477 · doc4.xml · derivative · entry 1 Kohler Terry · CIK 0001872285 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-07-15 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on July 16, 2022 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.